Companies To Watch
The Companies to Watch column spotlights small, entrepreneurial biopharma companies that are developing their own products (not just a platform) with little or no press coverage to date, and offering an interesting story involving useful business lessons.
-
![CtW_Teresa_Whalen_Cytoagents_450x300]( "Companies To Watch: CytoAgents")
Companies To Watch: CytoAgentsCytoAgents is combatting the broad areas of disease stemming from a common cause: cytokine release syndrome.
-
![CtW - Viking_Brian Lian_450x300]( "Companies To Watch: Viking Therapeutics")
Companies To Watch: Viking TherapeuticsViking Therapeutics is a broad-target contender for treating NASH in a pipeline of new drugs for metabolic and endocrine disorders.
-
![CtW_Florent Gros_300CMYK]( "Companies To Watch: Priothera")
Companies To Watch: PriotheraPriothera is bent on boosting the safety and effectiveness of hematopoietic stem cell transplantation for blood cancers.
-
![CtW - Mirum_450x300]( "Companies To Watch: Mirum Pharmaceuticals")
Companies To Watch: Mirum PharmaceuticalsMirum Pharmaceuticals: Two drugs, one FDA approved, together taking on a half-dozen rare liver diseases.
-
![CtW - CinCor_450x300]( "Companies To Watch: CinCor Pharma")
Companies To Watch: CinCor PharmaCinCor Pharma is uncovering a great potential for combatting treatment-resistant and uncontrolled hypertension.
-
![CtW - Castle Creek_450x300]( "Companies To Watch: Castle Creek Biosciences")
Companies To Watch: Castle Creek BiosciencesFor Castle Creek Biosciences, there are many stakes at play in targeting rare skin, connective tissue, liver, and metabolic disorders.
-
![CtW - Global Blood Therapeutics_450x300]( "Companies To Watch: Global Blood Therapeutics")
Companies To Watch: Global Blood TherapeuticsGlobal Blood Therapeutics is intertwining science, business, and social missions to make progress against sickle cell disease.
-
![CTW - Russ_450x300]( "Companies To Watch: Endevica Bio")
Companies To Watch: Endevica BioEndevica Bio is developing a new treatment for cachexia, a severe wasting disease critical to patients’ survival in cancer and other conditions.
-
![CTW_MiroBio_450x300]( "Companies To Watch: MiroBio")
Companies To Watch: MiroBioMiroBio is precisely targeting checkpoint receptors with agonist antibodies for better treatments in autoimmunity.
-
![CtW - Qlaris_450x300]( "Companies To Watch: Qlaris Bio")
Companies To Watch: Qlaris BioQlaris Bio is striking at an unaddressed target in the intraocular pressure of glaucoma.
-
![Ctw_Graphite Bio_450x300]( "Companies To Watch: Graphite Bio")
Companies To Watch: Graphite BioGraphite Bio focuses on precise repair of genes that cause sickness, starting with Sickle Cell Disease.
-
![CtW Atea_450x300]( "Companies To Watch: Atea Pharmaceuticals")
Companies To Watch: Atea PharmaceuticalsAtea Pharmaceuticals is creating new nucleotide antivirals, including one the company is jointly developing with Roche to fight COVID-19.
-
![CtW_Judy Chou 450x300]( "Companies To Watch: AltruBio")
Companies To Watch: AltruBioAltruBio’s new approach — regulating a checkpoint to mediate T cells in immune diseases — can surprise people more familiar with checkpoint-blocking cancer treatments now on the market.
-
![CtW_AMO_Ibraheem Mahmood_450x300]( "Companies To Watch: AMO Pharma")
Companies To Watch: AMO PharmaAMO Pharma is applying “de-risked” compounds as potential medicines for rare diseases in brain development.
IN THIS MONTH'S ISSUE
BEYOND THE PRINTED PAGE
-
MAPS: Walking The Talk On Intellectual Property?4/29/2022
Did MAPS, a leader in the psychedelic medicines space, just make good on its promise to share its intellectual property, as opposed to wielding it against competitors?
-
Where Patients Meet Policy: The EveryLife Foundation For Rare Diseases4/1/2022
The year before he founded Ultragenyx, Emil Kakkis created the EveryLife Foundation for Rare Diseases, a nonprofit patient advocacy organization focused on the “equitable development of and access to lifesaving diagnoses, treatments, and cures.” We caught up with Annie Kennedy, chief of policy and advocacy at the EveryLife Foundation, to learn more about the issues and policies the foundation is prioritizing this year.
-
Ever Learn A Lesson The Hard Way?1/24/2022
Bernard Coulie, M.D., Ph.D., president and CEO of Pliant Therapeutics, a company developing treatments for fibrotic diseases, shares a lesson learned the hard way involving an exit from a previous startup.
LIFE SCIENCE LEADER BLOGS
-
![2021_Rob Wright headshot]( "How Will It End?")
The decision by J.P. Morgan to make the 2022 annual healthcare conference fully virtual, inspires reflection on the past and advocacy for the future, in this final blog by Rob Wright, retired chief editor, Life Science Leader.
-
![Back to the office]( "When Will Biopharma Be Back In The Office?")
Three biopharmaceutical executives discuss plans around their company getting back to in-office operations.
